Healthcare provider profile · identity verified

Raul San Juan

Allopathic & Osteopathic Physicians|Internal Medicine · FORT LAUDERDALE, FL · NPI 1124489331

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show Raul San Juan received $233.24 in general payments during 2025 across 2 reported records.

Novo Nordisk Inc accounted for 52.2% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 1 associated product.

Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Jardiance by this doctor in 2024.

Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Ozempic by this doctor in 2024.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$233.24

2 reported records · 2 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported company	Canonical company	Amount	Share	Records	Year
Novo Nordisk Inc	Unresolved — no canonical attribution shown	$121.83	52.2%	1	2025
Boehringer Ingelheim Pharmaceuticals, Inc.	Unresolved — no canonical attribution shown	$111.41	47.8%	1	2025

What were the payments for?

Payment categories

Category	Amount	Records
Food and Beverage	$233.24	2

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported product	Type	Reported company	Related amount*	Records	Year
Wegovy Normalized: wegovy	Drug	Novo Nordisk Inc	$121.83	1	2025
Source payment records 2025-11-20 · Novo Nordisk Inc · $121.83 · Open Payments source

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

Paying company	Payment year	Drug reported by same entity	Open Payments evidence	Part D	Claims	Beneficiaries
Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference	2025	JARDIANCE open payments reported associated product	CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583	Jardiance · 2024 Exact normalized brand match · 1 Part D row	32	17
Novo Nordisk Inc Exact reporting entity; no affiliate inference	2025	Ozempic open payments reported associated product	CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076	Ozempic · 2024 Exact normalized brand match · 1 Part D row	40	11

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Rosuvastatin Calcium	Rosuvastatin Calcium	372	195
Atorvastatin Calcium	Atorvastatin Calcium	314	155
Diclofenac Sodium	Diclofenac Sodium	251	174
Gabapentin	Gabapentin	249	119
Lisinopril	Lisinopril	238	111
Amlodipine Besylate	Amlodipine Besylate	202	93
Losartan Potassium	Losartan Potassium	201	92
Metformin Hcl	Metformin Hcl	192	102
Levothyroxine Sodium	Levothyroxine Sodium	187	75
Tizanidine Hcl	Tizanidine Hcl	166	118
Tamsulosin Hcl	Tamsulosin Hcl	145	67
Naproxen	Naproxen	136	99
Metoprolol Succinate	Metoprolol Succinate	135	61
Omeprazole	Omeprazole	132	81
Fluticasone Propionate	Fluticasone Propionate	130	79
Glipizide	Glipizide	121	52
Trazodone Hcl	Trazodone Hcl	111	56
Pantoprazole Sodium	Pantoprazole Sodium	105	56
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	94	41
Vitamin D2	Ergocalciferol (Vitamin D2)	91	76
Eliquis	Apixaban	87	36
Furosemide	Furosemide	86	51
Metformin Hcl Er	Metformin Hcl	81	43
Simvastatin	Simvastatin	76	39
Meclizine Hcl	Meclizine Hcl	75	49
Clopidogrel	Clopidogrel Bisulfate	73	31
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	67	30
Famotidine	Famotidine	65	34
Methylprednisolone	Methylprednisolone	65	53
Ibuprofen	Ibuprofen	64	41
Azithromycin	Azithromycin	61	55
Albuterol Sulfate Hfa	Albuterol Sulfate	59	37
Alendronate Sodium	Alendronate Sodium	56	24
Ciprofloxacin Hcl	Ciprofloxacin Hcl	56	48
Metoprolol Tartrate	Metoprolol Tartrate	56	29
Glimepiride	Glimepiride	51	26
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	51	21
Carvedilol	Carvedilol	48	27
Novolin 70-30 Flexpen	Insulin Nph Hum/Reg Insulin Hm	48	20
Ketoconazole	Ketoconazole	47	24
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	47	30
Donepezil Hcl	Donepezil Hcl	44	22
Hydrochlorothiazide	Hydrochlorothiazide	41	21
Duloxetine Hcl	Duloxetine Hcl	40	19
Ozempic	Semaglutide	40	11
Lactulose	Lactulose	39	28
Memantine Hcl	Memantine Hcl	39	20
Escitalopram Oxalate	Escitalopram Oxalate	37	18
Finasteride	Finasteride	37	17
Azelastine Hcl	Azelastine Hcl	36	16
Bumetanide	Bumetanide	36	25
Baclofen	Baclofen	35	30
Meloxicam	Meloxicam	35	26
Sertraline Hcl	Sertraline Hcl	35	16
Alprazolam	Alprazolam	33	12
Hydrocortisone	Hydrocortisone	33	19
Jardiance	Empagliflozin	32	17
Hydralazine Hcl	Hydralazine Hcl	31	17
Quetiapine Fumarate	Quetiapine Fumarate	31	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	30	18
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	30	13
Montelukast Sodium	Montelukast Sodium	30	17
Pioglitazone Hcl	Pioglitazone Hcl	30	15
Atenolol	Atenolol	27	suppressed
Pregabalin	Pregabalin	27	15
Novolog Flexpen	Insulin Aspart	26	suppressed
Pravastatin Sodium	Pravastatin Sodium	26	11
Tramadol Hcl	Tramadol Hcl	26	17
Ultra-Fine Nano Pen Needle	Pen Needle, Diabetic	26	suppressed
Ofloxacin	Ofloxacin	25	23
Zolpidem Tartrate	Zolpidem Tartrate	25	suppressed
Ezetimibe	Ezetimibe	24	suppressed
Januvia	Sitagliptin Phosphate	24	suppressed
Glipizide-Metformin	Glipizide/Metformin Hcl	23	11
Temazepam	Temazepam	22	suppressed
Tadalafil	Tadalafil	21	suppressed
Betamethasone Dipropionate	Betamethasone Dipropionate	20	12
Doxycycline Monohydrate	Doxycycline Monohydrate	20	19
Methocarbamol	Methocarbamol	20	12
Sildenafil Citrate	Sildenafil Citrate	19	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	19	11
Amitriptyline Hcl	Amitriptyline Hcl	18	suppressed
Latanoprost	Latanoprost	18	suppressed
Tresiba Flextouch U-100	Insulin Degludec	18	suppressed
Trulicity	Dulaglutide	18	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	17	suppressed
Clonidine Hcl	Clonidine Hcl	16	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	15	15
Clonazepam	Clonazepam	15	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	15	suppressed
Folic Acid	Folic Acid	15	suppressed
Nifedipine Er	Nifedipine	15	suppressed
Ondansetron Odt	Ondansetron	14	11
Spironolactone	Spironolactone	14	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	14	suppressed
Humalog Kwikpen U-100	Insulin Lispro	13	suppressed
Humulin 70/30 Kwikpen	Insulin Nph Hum/Reg Insulin Hm	13	suppressed
Irbesartan	Irbesartan	13	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	13	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	13	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	13	11
Torsemide	Torsemide	13	suppressed
Allopurinol	Allopurinol	12	suppressed
Clobetasol Propionate	Clobetasol Propionate	12	suppressed
Mupirocin	Mupirocin	12	11
Paxlovid	Nirmatrelvir/Ritonavir	12	suppressed
Buspirone Hcl	Buspirone Hcl	11	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	11	suppressed
Droplet Pen Needle	Pen Needle, Diabetic	11	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	11	suppressed
Lidocaine	Lidocaine	11	suppressed
Mounjaro	Tirzepatide	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	$233.24 · 2 records	Novo Nordisk Inc	Wegovy	2	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error